- Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
- Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
- Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Key statistics
On Friday, Rocket Pharmaceuticals Inc (RCKT:NMQ) closed at 19.96, 34.05% above the 52 week low of 14.89 set on Aug 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.96 |
---|---|
High | 20.00 |
Low | 19.57 |
Bid | 19.00 |
Offer | 21.45 |
Previous close | 20.03 |
Average volume | 1.48m |
---|---|
Shares outstanding | 90.78m |
Free float | 85.86m |
P/E (TTM) | -- |
Market cap | 1.82bn USD |
EPS (TTM) | -2.87 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼